

Please try another search
(Reuters) - The U.S. National Institutes of Health (NIH) on Thursday launched a virtual program aimed at making antiviral treatments for COVID-19 available at home for those who test positive.
Local and state officials from Berks County in Pennsylvania will be the first to pilot the program, known as Home Test to Treat, later this month, with up to 8,000 residents expected to participate, the NIH said.
eMed, a privately-owned at-home health services firm, will host the official Home Test to Treat website, where individuals can sign up to receive antiviral treatment delivery as well as to coordinate telehealth-enabled test kits.
The public health agency has also engaged the UMass Chan Medical School in Worcester, Massachusetts, to collaborate with eMed on analyzing the data collected from the telehealth program such as the impact of a home-based process on testing and treatment.
The program, which was first announced in September by the White House, is aimed at increasing access for people in rural and high-risk communities.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review
Add a Comment
We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:
Enrich the conversation, don’t trash it.
Stay focused and on track. Only post material that’s relevant to the topic being discussed.
Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.
Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.